

# When is It Health Data and When is It Not?

Data about a person's health is a special category of data which requires a higher level of data protection than many developers of health-related apps and devices are aware of. Moreover, it is not always obvious when data becomes health data. We share the highlights from a new guidance from the Working Party on the subject.

By Thomas Bjørn and David Hobson

Over the past years, we have seen a rapid growth in the market for health and fitness-related apps and devices, covering a large variety of fields of use, with recent examples ranging from general warning systems tracing the development of infectious diseases and platforms for app developers like Apple HealthKit over downloadable mobile apps to medical devices for professional use.

The common feature shared by most of these developments is the collection of data which regularly includes personal data.

Data protection has become an issue of increasing importance in the digital era. If the personal data collected by apps and devices are classified as health data, then they have to be appropriately protected and can only be processed if the data subject "unambiguously" gives his consent which must be clear, knowingly given and limited to a specific purpose.

## But when is it health data ?

For developers and users of the rapidly increasing number of health-related apps, this is a very important question and an issue on which legal certainty is required. At the request of the Europe-

an Commission, the Working Party has therefore recently published guidance regarding the use of health data which provides some warnings but also useful advice to developers and operators of apps and devices.

## 3 Types of Health Data

Article 8 of the Data Protection Directive (95/46/EC) classifies health data as a special category of data which requires a higher level of data protection. The processing of such data is generally prohibited, unless an exception applies such as the express

consent of the data subject.

The Directive, however, does not offer a definition of "health data" – it merely lists the term together with other "special categories", so up to now it has been unclear what the term actually means.

As a result, the numerous providers of health and wellbeing apps and devices may have been at risk of processing data in breach of the Directive and its implementation into national law. It is therefore helpful that the Working Party has now offered some guidance as to the kind

## ABOUT THE AUTHORS

**THOMAS BJØRN** works as a solicitor with Royds LLP in London. His areas of expertise include the protection and commercialisation of intellectual property, regulatory affairs and the sale of goods and services to the NHS. Royds LLP is a London City based law firm providing legal services to the international business community. The firm specialises in commercial law and has a strong focus on intellectual property and the life science industries.

**DAVID HOBSON** is a part-qualified patent attorney at Mathys & Squire, which is one of Europe's most established and renowned specialist IP firms, with specialist attorneys in a wide range of technical fields including biotechnology, pharmacology, electronics, engineering and more. David Hobson has experience of drafting and prosecuting UK, European and foreign patent applications for a wide range of technologies pertaining to the field of biotechnology.



of data covered by the term.

The guidance makes it clear that health data can be classified into three categories:

- Data that are inherently/clearly medical data;
- Data that are raw sensor data that can be used alone or in combination with other data to draw a conclusion about the actual health status or health risk for a person; and
- Conclusions – whether accurate or not – about a person’s health status or health risk.

The term includes the obvious health data, i.e. data about the physical or mental health status of an individual, their medical history, diagnosis and treatment, together with any data gen-

erated by apps or devices which are used in this context. However, at its broadest interpretation the guidance concludes that health data can be seen to be any data about an individual that can be associated with a condition or allow some kind of diagnosis or inference about health status.

For example, data encompassed by this definition could include (amongst others) information about a person’s drinking or smoking habits, membership of patient support groups or use of corrective glasses .

Clearly, this has important ramifications for health and wellbeing application developers who must strive to ensure that such data is protected in accordance with the relevant EU directives and national law.

At the other end of the spectrum, the Working Party recognises that there are categories of data generated by apps and devices which must be classified as raw, low privacy impact personal data. As an example, the guidance mentions an app counting the number of steps during a single walk or making a single registration of a person’s weight, blood pressure or pulse. As no interpretation of the health status of the data subject can be made from such data, they cannot be classified as health data. It is, however, important to note that such low-impact information can very easily change into health data. If distance walked, weight and pulse are measured over time and/or used in combination with other information including diet, age, sex or even location data, it will be

ADVERT

## Life Science Companies Need a Highly Specialised Legal Partner

Mazanti-Andersen Korsø Jensen has a lot of experience in advising players and investors within the life science industry about business and legal matters.

The firm has a highly specialised department with many years of experience, including in-house experience in life sciences.

For the team, a deep knowledge of the industry and its needs and challenges is the key to a successful partnership with life science players.

“We have to be able to understand the context of the client’s problems,” says associate partner Sune Nyland. Equity partner Niels Walther-Rasmussen adds:

“It’s not enough to know the law. It is also essential to have insight into the industry in order to understand which challenges they face and to be able to advise them in a precise and relevant way. They live in a universe that is incredibly complicated legally. They have to meet complicated regulatory requirements, and at the same time provide capital for



Niels Walther-Rasmussen  
nwr@mazanti.dk



Sune Reinholdt Nyland  
srn@mazanti.dk



Lars Lütthjohan Jensen  
lj@mazanti.dk

large research costs and make sure to protect intellectual property rights. They are highly specialised people in these companies, but they are not lawyers. Therefore, the industry needs specialist advice and a trusted advisor. We combine thorough legal knowledge with hands-on experience of the industry and a business-oriented approach. To have an experienced legal partner with a thorough knowledge of the industry, our clients are much better positioned in relation to ensuring their place in the market,” concludes Niels Walther-Rasmussen.

Mazanti-Andersen Korsø Jensen helps many large companies, but also start-up companies.

“We are there right from the conception of a bright idea, until the invention is protected and the company can go public,” says Niels.

Most recently, Mazanti helped the company Ascendis Pharma to go public on the NASDAQ in New York.

“It is incredibly satisfying when it is a company you have followed from the very beginning,” concludes Sune Nyland.

### FACTS ABOUT

Mazanti-Andersen Korsø Jensen Law Partners

Advises on all relevant matters of life science and medico.

- IP Law
- M & A
- Regulatory and Contractual Matters
- Venture Capital
- Capital Markets

www.mazanti.com info@mazanti.dk

**mazanti-andersen**  
**korsø jensen &**

possible to draw conclusions about the health status of the data subject. If such conclusions can be drawn, the data will – regardless of whether the conclusions are correct or not – be regarded as health data and will be subject to the general prohibition in Article 8 of the Directive. The guidance recognises that for the functioning of some health apps it will not always be necessary to transfer the data off the device.

If the data processing takes place on the device itself and no personal data are transmitted outside the device, the processing will be covered by Article 3 (2) of the Directive and will therefore be exempt from the legislation.

### If It is Health Data You Need Explicit Consent

If the operator of the app or device (the data processor) collects data which amount to health data as defined above, he can only do so by relying on one of the exemptions in Article 8. In relation to the processing of health data from apps and devices, the relevant exemption is consent. Article 7 (a) requires that the data subject “unambiguously” gives his consent which must be clear, knowingly given and limited to a specific purpose. This is highly burdensome, both for the data processor and for the data subject.

The guidance provided by the Working Party is much needed given the growth in popularity of health and wellbeing apps, devices and wearable technology, with an expectation

of further growth in the coming years. The guidance also reveals new challenges for health and wellbeing application developers who must ensure the appropriate protection, responsible processing and storage of health data belonging to data subjects. The question is whether or not such requirements are realistic in the digital era – but that is another discussion. The Article 29 Working Party is composed of representatives from the data protection authorities of the EU member states and acts as an independent European advisory body on data protection and privacy.

Although not legally binding, the opinions of the Working Party are regularly referred to in legal decisions in the member states.



It's not the formula of the tablet alone that does the job.

It's also the **patent experts** protecting it.

Your navigator to competitive power®



We provide creative and tailored solutions within all aspects of patents, trademarks and designs.

Read more about our services at [pv.eu](http://pv.eu)

**Plougmann & Vingtoft**  
intellectual property consulting